U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ABSOLUTE
Molecular Formula C55H83N17O21S3
Molecular Weight 1414.544
Optical Activity UNSPECIFIED
Defined Stereocenters 19 / 19
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of BLEOMYCIN A2

SMILES

C[C@@H](O)[C@H](NC(=O)[C@@H](C)[C@H](O)[C@@H](C)NC(=O)[C@@H](NC(=O)C1=NC(=NC(N)=C1C)[C@H](CC(N)=O)NC[C@H](N)C(N)=O)[C@@H](O[C@@H]2O[C@@H](CO)[C@@H](O)[C@H](O)[C@@H]2O[C@H]3O[C@H](CO)[C@@H](O)[C@H](OC(N)=O)[C@@H]3O)C4=CN=C[N-]4)C(=O)NCCC5=NC(=CS5)C6=NC(=CS6)C(=O)NCCC[S+](C)C

InChI

InChIKey=OYVAGSVQBOHSSS-UAPAGMARSA-N
InChI=1S/C55H83N17O21S3/c1-20-33(69-46(72-44(20)58)25(12-31(57)76)64-13-24(56)45(59)82)50(86)71-35(41(26-14-61-19-65-26)91-54-43(39(80)37(78)29(15-73)90-54)92-53-40(81)42(93-55(60)88)38(79)30(16-74)89-53)51(87)66-22(3)36(77)21(2)47(83)70-34(23(4)75)49(85)63-10-8-32-67-28(18-94-32)52-68-27(17-95-52)48(84)62-9-7-11-96(5)6/h14,17-19,21-25,29-30,34-43,53-54,64,73-75,77-81H,7-13,15-16,56H2,1-6H3,(H13-,57,58,59,60,61,62,63,65,66,69,70,71,72,76,82,83,84,85,86,87,88)/t21-,22+,23+,24-,25-,29-,30+,34-,35-,36-,37+,38+,39-,40-,41-,42-,43-,53+,54-/m0/s1

HIDE SMILES / InChI

Description

Bleomycin sulfate is an antineoplastic antibiotic isolated from Streptomyces verticillus. It is a mixture of glycopeptide antibiotics containing primarily Bleomycin A2 (~70%) and B2 (~30%). Bleomycin binds to DNA, inhibits DNA synthesis, and causes single strand scission of DNA in vivo and in vitro at specific base sequences.

CNS Activity

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency
20.0 µM [Kd]

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
BLEOMYCIN SULFATE
Primary
BLEOMYCIN SULFATE
Primary
BLEOMYCIN SULFATE
Primary
BLEOMYCIN SULFATE
Primary
BLEOMYCIN SULFATE
Primary
BLENOXANE
Primary
BLENOXANE
Primary
BLENOXANE
Primary
BLENOXANE
Primary
BLENOXANE
Primary
BLENOXANE
Primary
BLENOXANE
Primary
BLENOXANE
Primary
BLENOXANE

Cmax

ValueDoseCo-administeredAnalytePopulation
80 μU/mL
150 unit single, intraperitoneal
BLEOMYCIN serum
Homo sapiens
318 ng/mL
15 mg single, intramuscular
BLEOMYCIN serum
Homo sapiens

AUC

ValueDoseCo-administeredAnalytePopulation
1192 ng × h/mL
15 mg single, intramuscular
BLEOMYCIN serum
Homo sapiens

T1/2

ValueDoseCo-administeredAnalytePopulation
5 h
150 unit single, intraperitoneal
BLEOMYCIN serum
Homo sapiens
2.5 h
15 mg single, intramuscular
BLEOMYCIN serum
Homo sapiens

PubMed

Sample Use Guides

In Vivo Use Guide
0.25 to 0.50 units/kg weekly or twice weekly (Squamous cell carcinoma, non-Hodgkin’s lymphoma, testicular carcinoma, Hodgkin’s disease)
Route of Administration: Intravenous
In Vitro Use Guide
1-200 ug/ml